Search results
We’re on the road with a new approach to clinical trials—one that expands access to cutting-edge medicines and treatments. Lilly is a medicine company turning science into healing to make life better for people around the world.
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Jun 25, 2024 · The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
We’re a medicine company turning science into healing to make life better for people around the world. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges.
Lilly introduced Humulin ® (human insulin derived from rDNA, Lilly), insulin identical to that produced by the human body, and the world’s first human-health-care product created using recombinant DNA technology.
Jun 25, 2024 · INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI 's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.
Recent Press Releases. View All Press Releases. Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease. July 2, 2024. Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria. June 25, 2024.
Jul 2, 2024 · The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
Eli Lilly and Company works tirelessly to develop and deliver trusted medicines that meet real needs. These include Trulicity, Humalog, Alimta, Forteo, Taltz, Humulin, Basaglar, Jardiance, Cyramza, REYVOW, Verzenio, Emgality and more.
Jul 8, 2024 · Eli Lilly & Co. agreed to buy U.S. gut-drug maker Morphic Holding Inc. for about $3.2 billion, plowing some of the proceeds from obesity blockbuster Zepbound into its experimental pipeline.
